TissGeneSummary for ZNF683 |
Gene summary |
Basic gene information | Gene symbol | ZNF683 |
Gene name | zinc finger protein 683 | |
Synonyms | - | |
Cytomap | UCSC genome browser: 1p36.11 | |
Type of gene | protein-coding | |
RefGenes | NM_001114759.1, NM_173574.2, | |
Description | hypothetical protein MGC33414 | |
Modification date | 20141207 | |
dbXrefs | HGNC : HGNC | |
Ensembl : ENSG00000176083 | ||
HPRD : 14563 | ||
Vega : OTTHUMG00000003521 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_ZNF683 | |
BioGPS: 257101 | ||
Pathway | NCI Pathway Interaction Database: ZNF683 | |
KEGG: ZNF683 | ||
REACTOME: ZNF683 | ||
Pathway Commons: ZNF683 | ||
Context | iHOP: ZNF683 | |
ligand binding site mutation search in PubMed: ZNF683 | ||
UCL Cancer Institute: ZNF683 | ||
Assigned class in TissGDB* | B | |
Included tissue-specific gene expression resources | HPA,TiGER,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
Reference showing the relevant tissue of ZNF683 | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for ZNF683 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
KICH | 0.459657834 | -1.396278166 | 1.855936 | 6.01E-06 | 1.99E-05 |
KIRC | 1.295699889 | -1.544740388 | 2.840440278 | 1.32E-24 | 1.52E-23 |
KIRP | 0.225625584 | -0.996736916 | 1.2223625 | 0.00579 | 0.013452 |
LUSC | 0.952834775 | 2.277532814 | -1.324698039 | 5.66E-05 | 0.000120135 |
Top |
TissGene-miRNA for ZNF683 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for ZNF683 |
TissGeneSNV for ZNF683 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.D79N | SKCM | 2 |
p.R249Q | STAD | 1 |
p.H424D | SKCM | 1 |
p.Q129H | UCEC | 1 |
p.Q162H | UCEC | 1 |
p.C324Y | PRAD | 1 |
p.K121E | LGG | 1 |
p.G264V | LUAD | 1 |
p.G422R | SKCM | 1 |
p.V240A | UCEC | 1 |
p.A42G | LIHC | 1 |
p.R348H | STAD | 1 |
p.R297L | SKCM | 1 |
p.H444D | SKCM | 1 |
p.A72E | STAD | 1 |
p.D51H | OV | 1 |
p.D95N | UCEC | 1 |
p.T94I | STAD | 1 |
p.K121N | UCEC | 1 |
p.R272Q | SKCM | 1 |
p.S117F | SKCM | 1 |
p.S263F | BLCA | 1 |
p.R432W | SKCM | 1 |
p.G54S | LUAD | 1 |
p.P349S | SKCM | 1 |
p.L199V | LUAD | 1 |
p.G422E | STAD | 1 |
p.R434S | LUAD | 1 |
p.A145P | COAD | 1 |
p.S180T | SARC | 1 |
p.H425Y | SKCM | 1 |
p.G434V | UCEC | 1 |
p.R418C | BLCA | 1 |
p.E484Q | HNSC | 1 |
p.K367* | LUAD | 1 |
p.P202T | UCS | 1 |
p.E242K | SKCM | 1 |
p.C76F | LUAD | 1 |
p.Q351K | STAD | 1 |
p.G402E | STAD | 1 |
p.A149S | UCEC | 1 |
p.S24F | SARC | 1 |
p.D48G | CESC | 1 |
p.G402R | SKCM | 1 |
p.P203S | UCEC | 1 |
p.W391* | BLCA | 1 |
p.G387R | HNSC | 1 |
p.S24N | UCEC | 1 |
p.M238L | KIRC | 1 |
p.D477Y | LUAD | 1 |
p.P299L | SKCM | 1 |
p.A115T | UCEC | 1 |
p.G54D | PAAD | 1 |
p.K329T | UCEC | 1 |
p.R272* | GBM | 1 |
p.T304A | HNSC | 1 |
p.P461L | SKCM | 1 |
p.L188I | UCEC | 1 |
p.R418G | LUAD | 1 |
p.S71Y | BRCA | 1 |
p.A248T | LGG | 1 |
p.P441S | UCEC | 1 |
p.D30N | SKCM | 1 |
p.L220F | SKCM | 1 |
p.P441L | SKCM | 1 |
p.G264S | GBM | 1 |
p.G144R | SKCM | 1 |
p.H445Y | SKCM | 1 |
p.A248T | COAD | 1 |
p.A171V | SKCM | 1 |
p.P91L | SKCM | 1 |
p.Q439K | BRCA | 1 |
p.D119N | COAD | 1 |
p.C175R | CHOL | 1 |
p.G93S | SKCM | 1 |
p.W471C | LUAD | 1 |
p.L211I | SKCM | 1 |
p.R434H | PRAD | 1 |
p.R376Q | PRAD | 1 |
p.A396V | LUAD | 1 |
p.L243V | LIHC | 1 |
p.E3K | SKCM | 1 |
p.L254F | SKCM | 1 |
p.R376W | COAD | 1 |
p.P203H | UCEC | 1 |
p.S269F | SKCM | 1 |
p.F150L | BLCA | 1 |
p.P169L | SKCM | 1 |
Top |
TissGeneCNV for ZNF683 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for ZNF683 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Top |
TissGeneNet for ZNF683 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for ZNF683 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for ZNF683 |
TissGeneDrug for ZNF683 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for ZNF683 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |
umls:C0263454 | Chloracne | 1 | CTD_human |
umls:C0376358 | Malignant neoplasm of prostate | 1 | BeFree |
umls:C0600139 | Prostate carcinoma | 1 | BeFree |
umls:C1561955 | Fibrinogen Adverse Event | 1 | GAD |